MedPath

Comparision of airway administration of drug to open up premature lungs (surfactant) with and without steroids in preventing chronic lung disease in premature babies

Not Applicable
Conditions
Health Condition 1: J984- Other disorders of lung
Registration Number
CTRI/2020/02/023310
Lead Sponsor
OT APPLICABLE
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Less than 6 hours of age

2.Receiving mechanical ventilation via an endotracheal tube or non-invasive respiratory support including CPAP, NIPPV and a clinical decision to treat the infant with exogenous surfactant (first or subsequent dose) for RDS

3.Prospective, written, informed parental/guardian consent obtained

Exclusion Criteria

1.Extreme preterm <24 weeks of gestation

2.Infant is considered non-viable or is not going to be admitted to intensive care

3.Known or suspected major congenital anomaly that is likely to affect respiratory status (eg: upper airway obstruction, severe pulmonary hypoplasia following oligohydramnios, congenital lung malformation, major congenital heart disease).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath